Efficacy News and Research

RSS
Scientists from University of Salzburg, Sandoz Pharmaceuticals and Thermo Fisher Scientific collaborate to advance protein-based pharmaceutical development

Scientists from University of Salzburg, Sandoz Pharmaceuticals and Thermo Fisher Scientific collaborate to advance protein-based pharmaceutical development

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

Angiochem presents results of Phase 2 study with ANG1005 in breast cancer patients with brain metastases

Angiochem presents results of Phase 2 study with ANG1005 in breast cancer patients with brain metastases

Influenza vaccination linked with reduced risk of adverse cardiovascular events

Influenza vaccination linked with reduced risk of adverse cardiovascular events

CSI receives PMA approval to market Diamondback 360 Coronary Orbital Atherectomy System

CSI receives PMA approval to market Diamondback 360 Coronary Orbital Atherectomy System

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

COPD treatments: an interview with Professor Price, University of Aberdeen

COPD treatments: an interview with Professor Price, University of Aberdeen

Psychotherapy: New treatment choice for anorexia nervosa

Psychotherapy: New treatment choice for anorexia nervosa

Capsugel launches Coni-Snap sprinkle capsule for people with difficulties swallowing

Capsugel launches Coni-Snap sprinkle capsule for people with difficulties swallowing

Clinical trials will help to develop treatment and follow-up of COPD patients

Clinical trials will help to develop treatment and follow-up of COPD patients

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

Guerbet receives FDA Orphan Drug Designation for Lipiodol Injection

Guerbet receives FDA Orphan Drug Designation for Lipiodol Injection

Research paper published by Scientific Reports details the efficacy of n3D's Apple iPhone app

Research paper published by Scientific Reports details the efficacy of n3D's Apple iPhone app

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

Anergis reports immunology data from AllerT Phase IIb study for birch pollen allergy

Anergis reports immunology data from AllerT Phase IIb study for birch pollen allergy

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.